Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease  by Bedogni, Alberto et al.
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bstract
anagement of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity
f disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including
he widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and
adiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease
ompared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate the
greement between the AAOMS staging system and the extent of osteonecrosis of the jaw (focal compared with diffuse involvement of bone)
s detected on CT. We studied 799 patients with detailed clinical phenotyping who had CT images taken. Features of diffuse bone disease
ere identified on CT within all AAOMS stages (20%, 8%, 48%, and 24% of patients in stages 0, 1, 2, and 3, respectively). Of the patients
lassified as stage 0, 110/192 (57%) had diffuse disease on CT, and about 1 in 3 with CT evidence of diffuse bone disease was misclassified
y the AAOMS system as having stages 0 and 1 osteonecrosis. In addition, more than a third of patients with AAOMS stage 2 (142/405, 35%)
ad focal bone disease on CT. We conclude that the AAOMS staging system does not correctly identify the extent of bony disease in patients
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ntroduction
steonecrosis of the jaw is a potentially severe side effect
f antiresorptive agents including aminobisphosphonates and
enosumab, the incidence of which is reported to vary from
 to 27.5% in patients treated with bisphosphonates intra-
enously, with a mean incidence of 7%.1 It typically presents
ith areas of necrotic avascular jawbone exposed through
he oral mucosa or facial skin.2 Infection of necrotic bone is
ommon and can lead to chronic pain, facial disfigurement,
mpaired function, and reduction of quality of life.3 Man-
gement of osteonecrosis of the jaw is challenging and there
s little evidence about the effectiveness of treatments.1 In
ost cases, the outcome is unpredictable. 4 Patients with mild
o moderate disease are usually offered minimally invasive
reatment such as control of infection and pain, and superfi-
ial debridement of bone, whereas it has been suggested that
hose with advanced and refractory disease may benefit from
esection. 2,5 Accurate staging is therefore crucial to making
herapeutic decisions and planning.
Staging of osteonecrosis of the jaw is currently based
n the classification proposed by the American Association
f Oral and Maxillofacial Surgery (AAOMS), which relies
n clinical and radiographic examinations.2 Other classifi-
ations are similarly based. 6,7 However, visual inspection
s likely to identify only superficial signs, which may not
ecessarily reflect the true extent of bony disease. 6,8,9 For
nstance, the non-exposed variant, which often presents with
inimal superficial clinical changes (such as a sinus tract),
an be associated with widespread underlying necrosis of the
aw. 10,11 Signs such as exposed bone, infection with mucosal
rythema, purulent discharge, and pain, however, may not be
ssociated with widespread bony disease.12 Studies have also
hown that routine dental radiographs (such as panoramic
adiography) is inferior to other imaging techniques in detec-
ing the extent of bony disease in osteonecrosis.13 A new
i
o
T
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omputed tomography; Antiresorptive agents
taging system has been proposed that integrates clinical
anifestations and CT findings.14 As the amount of research
rows, an increasing number of authors now report the use
f CT to study the extent of osteonecrosis in these patients.
5-17 There is, however, little evidence to suggest that the ben-
fits of CT are enough to justify its routine use for staging of
isease.
To test the hypothesis that the current staging system for
steonecrosis of the jaw may not correctly identify the extent
f disease because of the lack of data from CT, we evalu-
ted the agreement of AAOMS staging with CT imaging for
ssessment of the extent of bone disease (focal compared
ith diffuse).
atients  and  methods
esign  of  the  study
e performed a multicentre retrospective study known as
ISSION (Multicentre study on phenotype, defInition and
laSSification of osteONecrosIs of the jaws associated with
isphosphONates).
etting
esearch workers from the Universities of Verona, Palermo
Italy), and University College London (UK), designed the
tudy and sent a collaboration proposal to a network of Italian
entres of Oral Medicine and Oral and Maxillofacial Surgery
ith a special interest in the diagnosis and management of
steonecrosis of the jaw. The main requirements for partic-
pation were availability of a large group of patients with
steonecrosis, and routine use of CT in their investigations.
en centres replied and agreed to collaborate, so a total of
3 centres contributed to the MISSION study. The ethics
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ment between the AAOMS staging system and CT for the
detection of bone disease was evaluated by calculating the
proportion of patients with diffuse disease within each stageA. Bedogni et al. / British Journal of Ora
ommittees of the participating centres approved the study
nd patients’ consent to participate was obtained where
pecifically required. Collection of data was completed
etween March and December 2012. MISSION was con-
ucted with the partnership of the Italian Society of
axillofacial Surgery (SICMF) and of the Italian Society
f Oral Medicine and Pathology (SIPMO). The study was
eported according to STROBE recommendations.18
riteria  of  eligibility
atients referred to the participating centres between January
004 and December 2011 were eligible for MISSION if they
ad: exposed osteonecrosis of the jaw defined as the presence
f long-standing (more than 8 weeks) transmucosal expo-
ure of necrotic jawbone; unexposed ostenecrosis of the jaw
efined as the presence of otherwise unexplained pain in the
aw, fistula, swelling, mobile teeth, or mandibular fracture, as
efined by Fedele et al., and others;10,19 previous or current
reatment with bisphosphonates; no history of radiotherapy
o the jaws; no history of resection of the jaws; and availabil-
ty of CT (spiral or cone-beam) of the affected jaws. Only
atients with CT scans that had been done within 6 months
rom clinical phenotyping were included, so that we had some
greement between the clinical signs and the CT findings.
entascan reformatted images were not considered, as they
o not accurately display the ramus of the mandible and
he midfacial bones. Multidisciplinary teams that included
rescribers of bisphosphonates (oncologists, haematologists,
nd rheumatologists) and specialists in oral medicine or max-
llofacial surgery, or both, decided which cases were suitable
or inclusion.
ollection  of  data
ospital casenotes of consecutive patients with osteonecrosis
f the jaw diagnosed between January 2004 and December
011 were reviewed retrospectively. Clinical data relevant to
he study (see “Other  measurements”  below) were extracted
y local clinical teams and entered into a standard electronic
ase report form by one clinician at each centre (GS, Padua,
B Verona; GC, Palermo; SF, London; SV, Como; AA and
O, Rome; MS, Turin; GF, Bari; GC, Naples; GO, Messina;
G Pisa; and VF, Alessandria). They were also responsible
or the final allocation of patients into AAOMS stages. Radio-
ogists with experience and a special interest in head and neck
maging assessed and reported CT scans in all centres and
ere blinded to the patients’ AAOMS staging.
The medical statistician responsible for data analysis (GB)
anaged the database according to standard procedures. We
sed Stata 13.0 (Stata Corp., College Station, TX, US) pro-
rams to ensure reproducibility of methods.utcome  of  the  study
he study aimed to evaluate the degree of agreement
etween the AAOMS staging system and CT imaging for the
o
w
s
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ssessment of the extent of osteonecrosis (focal compared
ith diffuse).
easures  of  outcome
AOMS stages were defined as reported by Ruggiero et al.2
riefly, stage 0 included patients with clinical signs of
steonecrosis other than exposed bone. Stage 1 included
hose with exposed necrotic bone but no pain or suppu-
ation. Stage 2 included those with exposure of necrotic
one together with pain or suppuration, and stage 3 included
atients with exposed necrotic bone and an extraoral fistula,
equestration, or mandibular fracture. CT imaging comprised
ony windowing with both axial and coronal views. The
xtent of involvement of the jaw was decided by the extent
f sclerotic bony changes evaluated as the loss of contrast
etween the endosteal cortex and the subjacent medullary
one compared with healthy bone. Specific and reproducible
efinitions were used to differentiate between focal and dif-
use bony disease by spiral or cone-beam CT. In detail,
ocal bony disease was defined as osteosclerotic involvement
imited to alveolar bone, whereas diffuse bony disease was
efined as osteosclerotic involvement of both alveolar and
asal bone. 11,20 The choice of sclerotic bony changes as the
ain variable by which to study extension of disease was
ased on previous reports. 8,21,22
ther  measurements
he following data were collected from the casenotes: age,
ex, indication for prescription of bisphosphonates, type of
isphosphonate, duration of treatment, cumulative dose, con-
urrent use of steroids, concurrent use of antiangiogenic
gents (such as sunitinib and bevacizumab), presence of
nown risk factors for bisphosphonate-related osteonecrosis
such as extraction of teeth, dental or periodontal infec-
ion, ill-fitting prosthesis, or dental implant surgery), site
f osteonecrosis, and the presence of exposed bone, pain,
urulent discharge, extraoral fistula, displaced mandibular
tumps, and nasal leakage of fluids.
tatistical  analysis
ontinuous variables are reported as 25th, 50th, and 75th cen-
iles because of non-Gaussian distributions, and categorical
ariables are reported as counts or percentages. The agree-f AAOMS. The significance of differences was assessed
ith the help of Stata 13.0 (Stata, College Station, TX)
oftware. Stata programs were written to ensure the repro-
ucibility of the analysis.
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Table 1
Continuous measurements of the ONJ patients.
N P50 P25 P75
Age (years) 799* 69 62 75
Zoledronate (mg), iv. 621** 76 48 120
Pamidronate (mg), iv. 99** 2250 1200 4320
Alendronate (mg), oral 125** 13440 6160 23520
Neridronate (mg), iv. 2** 724 648 800
Risedronate (mg), oral 12** 5430 3360 11115
Ibandronate (mg), iv. 30** 3300 450 7200
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system may underestimate or overestimate the extent of bony
disease, with potentially serious repercussions on therapeutic
decisions.
Table 2
Categorical measurements for patients with osteonecrosis of the jaws.
Variable No (%)
Male sex 257 (32)
Drugs:
Zoledronate (intravenously) 621 (78)
Pamidronate (intravenously) 99 (12)
Alendronate (orally) 125 (16)
Neridronate (intravenously) 2 (<1)
Risedronate (orally) 15 (2)
Ibandronate (intravenously) 30 (4)
Other bisphosphonate 343 (43)
Steroids 224 (28)
Sunitinib 19 (2)
Bevacizumab 6 (1)
Clinical and radiological presentation:
Site - mandibular 518 (65)
Site - maxillary 281 (35)
Exposed bone 607 (76)
Pain 623 (78)
Purulent discharge 598 (75)
Cervical fistula 95 (12)
Dislocated stump 32 (4)
Nasal leakage 48 (6)
Focal disease on computed tomography 254 (32)
Underlying disease:
Cancer of the breast 256 32)
Renal cancer 30 (4)
Cancer of the prostate 103 (13)
Cancer of the thyroid 2 (<1)
Bronchial cancer 15 (2)
Other solid tumours 39 (5)
Myeloma 210 (26)
Osteoporosis 139 (17)
Metabolic disease 21 (3)
Oral risk factors:
Tooth extraction 434 (54)
Prosthesis 66 (8)Total number of subjects
∗∗ Number of subjects who took the given bisphosphonate Abbreviations:
esults
etails  of  the  group  studied
verall, the data from 886 patients were collected by the
tudy centres and sent to the scientist in charge of data anal-
sis (GB). Eighty-seven of these 886 patients (10%) had one
r more piece of missing or conflicting data among those
equired by the protocol and were excluded from analysis.
99 patients aged 29–94 years were available for the final
nalysis. All measurements made of the final study group are
eported in Tables 1 and 2.
greement  between  AAOMS  staging  and  CT  imaging  for
he assessment  of  the  extent  of  osteonecrosis
able 3 shows the number of patients with local or diffuse
isease shown on CT for each AAOMS stage. Overall 545
atients (68%) had diffuse bone disease. Stages 0,1,2 and
 were associated with CT evidence of diffuse disease in
7%, 58%, 65% and 100% of cases, respectively. Of the
45 patients with diffuse bone disease at CT, 20% (95%CI
7–24%, n  = 110) were in AAOMS stage 0, 8% (5%–10%,
 = 42) in AAOMS stage 1, 48% (44–52%, n  = 263) in
AOMS stage 2 and 24% (20–27%, n  = 130) in AAOMS
tage 3.
iscussion
e have investigated the degree of agreement between the
AOMS staging system and CT imaging for correct identi-
cation of the extent of osteonecrosis.
Accurate staging is essential to plan the correct treatment
or affected patients. The most common staging system is
hat devised by the AAOMS, which has been used in most
tudies.2 Such a system relies on clinical signs and does not
nclude imaging of the jaws except that provided by den-
al radiographs. Other classification systems have a similar
6,7tructure. However, it has been increasingly reported that
uperficial clinical signs may not show the true extent of
ony disease, and the ability of routine dental radiographs
such as panoramic radiographs) to detect the extent of bone
I
I
O
Utravenous P50 = 50th percentile; P25 = 25th percentile; P75 = 75th percentile.
isease is poor compared with that of other imaging
echniques including CT and magnetic resonance imaging
MRI).13,21 It is possible, therefore, that the AAOMS stagingmplant 23 (3)
nfection 125 (16)
ther 4 (<1)
nidentified 149 (19)
A. Bedogni et al. / British Journal of Oral and M
Table 3
Number of patients with local or diffuse bone disease on computed tomo-
graphy for each American Association of Oral and Maxillofacial Surgeons’
stage. Data are number (%).
Stages Focal Diffuse Total
0 82 (32) 110 (20) 192 (24)
1 30 (12) 42 (8) 72 (9)
2 142 (56) 263 (48) 405 (51)
3 0 130 (24) 130 (16)
Total 254 (100) 545 (100) 799 (100)
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scans of the study patients. Authors acknowledge the ItalianWe found poor agreement between the AAOMS staging
ystem and CT findings in patients with osteonecrosis. Dif-
use bone disease was detected by CT within all AAOMS
tages. About 1 in 3 of all patients with diffuse bone dis-
ase was misclassified as having less severe disease by the
AOMS system. If we focus on stage 0, over half of those
atients had diffuse disease on CT, which confirmed that the
bsence of clinically evident exposed bone is not a sign of
ow stage osteonecrosis (extension or severity of disease, or
oth).14
In addition, more than a third of patients with AAOMS
tage 2 disease (35%) had focal bone disease on CT, showing
hat the presence of exposed bone, pain, and suppuration does
ot necessarily indicate a more severe stage of disease and can
e associated with limited extension. Only AAOMS stage 3
howed good agreement with CT imaging, as all the patients
n this group had diffuse disease.
Overall, our results have shown that AAOMS stages are
nlikely to identify correctly the extent of involvement of the
aw with the exception of AAOMS stage 3 disease, which
orrectly identified an homogeneous group of patients with
iffuse abnormalities of the jaw on CT imaging.
This study has a number of strengths, including the size
f the group studied (to our knowledge the largest ever
eported), the multicentre design, the accurate description
f the outcome measurements, and CT imaging reported by
adiologists with a special interest in head and neck imag-
ng who were unaware of the patients’ AAOMS staging. The
ecruitment of centres that participated in the study was based
rincipally on their routine use of CT for the diagnosis and
ollow-up of osteonecrosis of the jaw. By doing this, data
elevant to consecutive affected patients diagnosed between
004 and 2011 in the participating centres could be analysed,
hich minimised the risk of selection bias. Although routine
se of CT is not part of most available diagnostic recommen-
ations or classification systems, 2 a number of Italian groups
ave focused their research on the potential advantages of
T in the measurement of the extent of bony involvement in
atients with osteonecrosis. 8,21 There has been increasingly
obust evidence published about the superiority of CT, as well
s MRI, over panoramic radiography 11,20,22 in the investiga-
ion of osteonecrosis over the last few years, and this accounts
or its routine use today in the centres that participated in the
resent study.
S
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Limitations of the study include its retrospective design
nd limited geographical variability, with all centres but one
eing in Italy. The decision to use the extent of osteoscle-
otic changes as the main variable to define extension of
steonecrosis on CT may seem questionable. However,
he presence of osteosclerosis in clinically symptomatic
reas of the jaws has clearly been reported as a consis-
ent CT feature, both in initial and advanced forms of
steonecrosis. 8,11,20–22 Most of the other well-recognised
T features of osteonecrosis (such as sequestra, osteolysis,
eactive periostitis, and sinusitis) are not found consistently
nd are mainly associated with advanced stages of the
isease.12,23
AAOMS stage 3 was the only stage that correctly iden-
ified a homogeneous group of patients with extensive and
dvanced disease. These findings may help to explain previ-
us reports that the treatment of osteonecrosis in patients with
AOMS stage 3 disease is associated with more predictable
nd better outcomes than that of AAOMS stages 1 and 2.24 We
uggest that the variability of responses to treatment found
n patients with AAOMS stage 1 and 2 disease could reflect
he heterogeneity of the extent of disease (focal and diffuse)
ithin these 2 groups. The consistency of outcomes reported
n patients with AAOMS stage 3 may be related to the iden-
ification of a homogeneous group of patients with diffuse
isease.16,25
Recently, the Italian Societies of Oral Medicine and
axillofacial Surgery suggested a new staging system (the
ICMF-SIPMO staging system) based on the use of CT
maging and clinical signs (Appendix 2). 14 This integrated
lassification is our first non-validated attempt to improve
urrent staging systems for osteonecrosis, which we have
hown here to be at high risk of underestimating or overesti-
ating the extent of disease.
In the present study we have shown for the first time, to
ur knowledge, that the current AAOMS staging system is
ot accurate in identifying the extent of osteonecrosis, except
or stage 3. The therapeutic implications of this could be
mportant, as AAOMS staging is commonly used to guide
reatment. We suggest that future staging systems should
onsider both clinical signs and CT features with the aim of
escribing the extent of bony disease accurately, together with
ts associated symptoms. We also suggest that the results of
revious studies that have allocated treatment of osteonecro-
is using the AAOMS staging system should be interpreted
ith caution.
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